{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:10:15Z","timestamp":1789557015045,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The exponential increase in obesity is responsible for the increased prevalence of obstructive sleep apnoea (OSA). Weight loss is critical to improvement in OSA. Glucagon-like peptide-1 receptor (GLP1R) agonism-based therapies (GLP1RA-BT) have been associated with significant weight loss. Several randomized controlled trials have been published evaluating the use of GLP1RA-BT on OSA. However, the literature review revealed that no systematic review and meta-analysis (SRM) has been published evaluating the efficacy and safety of GLP1RA-BT in OSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Electronic databases were searched for studies documenting the use of GLP1RA-BT in OSA. The primary outcome was to evaluate the impact on the apnea\u2013hypopnea index (AHI). Secondary outcomes were to evaluate the impact on percent change in AHI, Epworth Sleepiness Score, body weight, blood pressure, and side-effect profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From initially screened 59 articles, data from 4 articles having 5 different randomized cohorts (937 patients) were analysed in this SRM. Use of GLP1RA-BT was associated with a significant reduction in AHI [MD-12.50 events\/ hour (95% CI:\u221217.33 \u2013 -7.67);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      =95%], percent-reduction in AHI [MD-52.17% (95% CI: -64.49 \u2013 -39.85);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%], percent-reduction in body-weight [MD-12.46% (95% CI:-22.54 \u2013 -2.39);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 99%] and systolic blood-pressure [MD -4.59 mm of Hg (95% CI:-6.61 \u2013 -2.58); P &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 67%]. The considerable heterogeneity was because of greater improvement in outcomes withtirzepatide compared to liraglutide. The occurrence of nausea [RR4.23 (95% CI: 2.73\u20136.55);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%], vomiting [RR4.22 (95% CI: 2.12\u20138.41);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%], diarrhoea [RR2.81 (95% CI: 1.84\u20134.31);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%], and constipation [RR4.51 (95% CI: 2.47\u20138.26);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%] were significantly higher with GLP1RA-BT compared to placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This SRM provides encouraging data on the use of GLP1RA-BT in improving different respiratory aspects of OSA and reducing body weight and blood pressure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_365_24","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T09:14:44Z","timestamp":1740734084000},"page":"4-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis"],"prefix":"10.4103","volume":"29","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Jindal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Raizada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan ABM","family":"Kamrul","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"R1-20250228","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(13)60734-5","article-title":"Adult obstructive sleep apnoea","volume":"383","author":"Jordan","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"R2-20250228","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41569-023-00846-6","article-title":"Obstructive sleep apnoea heterogeneity and cardiovascular disease","volume":"20","author":"Redline","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"R3-20250228","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-2600(19)30198-5","article-title":"Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis","volume":"7","author":"Benjafield","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R4-20250228","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201807-1326ST","article-title":"The role of weight management in the treatment of adult obstructive sleep apnea. An Official American Thoracic Society clinical practice guideline","volume":"198","author":"Hudgel","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-20250228","doi-asserted-by":"crossref","first-page":"72","DOI":"10.17925\/EE.2024.20.2.10","article-title":"Efficacy and safety of novel twincretin tirzepatide, a dual GIP\/GLP-1 receptor agonist, as an anti-obesity medicine in individuals without diabetes: A systematic review and meta-analysis","volume":"20","author":"Dutta","year":"2024","journal-title":"touchREV Endocrinol"},{"key":"R6-20250228","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11695-024-07175-8","article-title":"Glucagon-Like Peptide-1 receptor agonists in post-bariatric surgery patients: A systematic review and meta-analysis","volume":"34","author":"Dutta","year":"2024","journal-title":"Obes Surg"},{"key":"R7-20250228","doi-asserted-by":"crossref","first-page":"102539","DOI":"10.1016\/j.dsx.2022.102539","article-title":"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis","volume":"16","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"R8-20250228","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"R9-20250228","first-page":"1310","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes 2005"},{"key":"R10-20250228","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2023","journal-title":"Sleep Breath Schlaf Atm"},{"key":"R11-20250228","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R12-20250228","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"21","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R13-20250228","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R14-20250228","first-page":"1","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess Winch Engl"},{"key":"R15-20250228","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med?"},{"key":"R16-20250228","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1513\/AnnalsATS.202309-821OC","article-title":"Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: A randomized proof-of-concept study","volume":"21","author":"O'Donnell","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"R17-20250228","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10072-021-05765-3","article-title":"The effect of obstructive sleep apnea on the increased risk of cardiovascular disease: A systematic review and meta-analysis","volume":"43","author":"Salari","year":"2022","journal-title":"Neurol Sci"},{"key":"R18-20250228","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1002\/osp4.743","article-title":"Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis","volume":"10","author":"Dutta","year":"2024","journal-title":"Obes Sci Pract"},{"key":"R19-20250228","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/XCS.0000000000001047","article-title":"Remission of obesity-related sleep apnea and its effect on mortality and cardiovascular events after metabolic and bariatric surgery: A propensity matched cohort study","volume":"239","author":"Stenberg","year":"2024","journal-title":"J Am Coll Surg"},{"key":"R20-20250228","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s11695-024-07124-5","article-title":"Obstructive sleep apnea: The effect of bariatric surgery after five years-A Prospective multicenter trial","volume":"34","author":"Peromaa-Haavisto","year":"2024","journal-title":"Obes Surg"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_365_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:51:44Z","timestamp":1786647104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_365_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_365_24","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}